Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

被引:229
作者
Montefiori, DC [1 ]
Pantaleo, G [1 ]
Fink, LM [1 ]
Zhou, JT [1 ]
Zhou, JY [1 ]
Bilska, M [1 ]
Miralles, GD [1 ]
Fauci, AS [1 ]
机构
[1] NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892
关键词
D O I
10.1093/infdis/173.1.60
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term nonprogressors (LTNPs) and non-LTNPs were evaluated for virus neutralization and infection enhancement in vitro. Sera from LTNPs had higher average titers of neutralizing antibodies to HIV-1 strains IIIB and MN and more frequently neutralized primary isolates from progressors (14.9% vs, 1.3%, P = .002). Replication-competent HIV-1 was isolated from peripheral blood mononuclear cells and lymph nodes of 3 LTNPs. All viruses from LTNPs had a non-syncytium-inducing phenotype, were resistant to neutralization by autologous serum obtained at the time of virus isolation, and showed little evidence of a heightened sensitivity to neutralization by heterologous sera. Complement-mediated, antibody-dependent enhancement (C'-ADE) of HIV-1(IIIB) and primary isolates was equally prevalent for sera from LTNPs and non-LTNPs. Results indicate that LTNPs produce vigorous serum antibody responses and that long-term nonprogression is not associated with homologous neutralization or the absence of C'-ADE.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 43 条
[1]   RAPID DEVELOPMENT OF ISOLATE-SPECIFIC NEUTRALIZING ANTIBODIES AFTER PRIMARY HIV-1 INFECTION AND CONSEQUENT EMERGENCE OF VIRUS VARIANTS WHICH RESIST NEUTRALIZATION BY AUTOLOGOUS SERA [J].
ALBERT, J ;
ABRAHAMSSON, B ;
NAGY, K ;
AURELIUS, E ;
GAINES, H ;
NYSTROM, G ;
FENYO, EM .
AIDS, 1990, 4 (02) :107-112
[2]  
ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303
[3]   AIDS - DO ANTIBODIES ENHANCE THE INFECTION OF CELLS BY HIV [J].
BOLOGNESI, DP .
NATURE, 1989, 340 (6233) :431-432
[4]   LONG-TERM HIV-1 INFECTION WITHOUT IMMUNOLOGICAL PROGRESSION [J].
BUCHBINDER, SP ;
KATZ, MH ;
HESSOL, NA ;
OMALLEY, PM ;
HOLMBERG, SD .
AIDS, 1994, 8 (08) :1123-1128
[5]  
BURKE DS, 1992, PERSPECT BIOL MED, V35, P511
[6]   VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CAO, YZ ;
QIN, LM ;
ZHANG, LQ ;
SAFRIT, J ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208
[7]   THE SAFETY AND IMMUNOGENICITY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) RECOMBINANT GP160 CANDIDATE VACCINE IN HUMANS [J].
DOLIN, R ;
GRAHAM, BS ;
GREENBERG, SB ;
TACKET, CO ;
BELSHE, RB ;
MIDTHUN, K ;
CLEMENTS, ML ;
GORSE, GJ ;
HORGAN, BW ;
ATMAR, RL ;
KARZON, DT ;
BONNEZ, W ;
FERNIE, BF ;
MONTEFIORI, DC ;
STABLEIN, DM ;
SMITH, GE ;
KOFF, WC .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (02) :119-127
[8]   NON-PROGRESSION IN HIV-INFECTION [J].
EASTERBROOK, PJ .
AIDS, 1994, 8 (08) :1179-1182
[9]   IMMUNOPATHOGENIC MECHANISMS IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION [J].
FAUCI, AS ;
SCHNITTMAN, SM ;
POLI, G ;
KOENIG, S ;
PANTALEO, G .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (08) :678-693
[10]   THE ROLE OF COMPLEMENT IN INFLAMMATION AND PHAGOCYTOSIS [J].
FRANK, MM ;
FRIES, LF .
IMMUNOLOGY TODAY, 1991, 12 (09) :322-326